Cat. No. | Product name | CAS No. |
DCC1792 |
Dihydromotuporamine C Trihydrochloride
Unique antimigration and antiangiogenic agent |
855997-15-8 |
DCC1793 |
Diic16tac
Novel lipid-based, high-density, environmentally sensitive (HIDE) probe |
|
DCC1794 |
Diic16'tco
Novel lipid-based, high-density, environmentally sensitive (HIDE) probe |
|
DCC1795 |
Dilazep
Vasodilator for the treatment of cardiopathy and renal disorders, acting as an adenosine reuptake inhibitor. |
35898-87-4 |
DCC1796 |
Dimenthyl (1s,2s)-cyclopropane-1,2-dicarboxylate
Building Block |
96149-00-7 |
DCC1797 |
Dimenthyl Succinate
Building Block |
34212-59-4 |
DCC1798 |
dimethacrine
Novel inhibitor of AMA1-RON2 interaction, blocking merozoite invasion from schizont-infected RBCs; Antidepressant; Acetylcholinesterase inhibitor |
4757-55-5 |
DCC1799 |
Dimethothiazine
Serotonin antagonist and histamine antagonist |
7456-24-8 |
DCC1800 |
Dimethoxy-etomidate
Novel analog of etomidate, potently inhibiting 11-beta-hydroxylase without GABAA receptor positive modulatory and sedative-hypnotic activities |
|
DCC1801 |
Diminazene
Anti-infective agent against certain protozoa such as Babesia, Trypanosoma, Cytauxzoon, and certain bacteria including Brucella and Streptococcus |
536-71-0 |
DCC1802 |
Dimiq Hydrochloride
Inhibitor of Topoisomerase>DNA topoisomerase II; very potent cytotoxic antitumor agent |
1011460-73-3 |
DCC1803 |
Dinalbuphine Sebacate
Long-lasting prodrug of nalbuphine, acting as a moderate-efficacy partial agonist or antagonist of the μ-opioid receptor and as a high-efficacy partial agonist of the κ-opioid receptor |
311768-81-7 |
DCC1804 |
Dinapsoline
Natural full D1 dopamine receptor agonist |
458563-40-1 |
DCC1805 |
Dipicrylamine Sodium Salt
Potent antagonist of GABA A receptors that contain alpha1 and beta2 subunits |
13474-21-0 |
DCC1806 |
Dipquo
Novel activator of the bone marker alkaline phosphatase (ALP), markedly promoting osteoblast differentiation, including expression of Runx2, Osterix, and Osteocalcin, mediating osteogenesis through activation of p38-β |
1269365-82-3 |
DCC1807 |
Dipraglurant
Novel negative allosteric modulator of the mGlu5 receptor |
872363-17-2 |
DCC1808 |
Displurigen
Inhibitor of ATPase activity of HSP70 |
96156-26-2 |
DCC1809 |
Distamycin A Hydrochloride
Antibiotic, specifically inhibiting the initiation of RNA synthesis, binding isohelically to the minor groove of B-DNA at A/T rich sites |
6576-51-8 |
DCC1810 |
Distigmine Dibromide
Parasympathomimetic with longer duration of action |
15876-67-2 |
DCC1811 |
Djt06001
Novel selective Factor Xa inhibitor, reducing thrombus formation with low risk of bleeding |
1628182-40-0 |
DCC1812 |
Dk-1-150
Novel inducer of apoptotic cell death in TNBC cell lines without causing cytotoxicity in the normal mammary epithelial cell line |
|
DCC1813 |
Dk-1-166
Novel inducer of apoptotic cell death in TNBC cell lines without causing cytotoxicity in the normal mammary epithelial cell line |
2204279-20-7 |
DCC1814 |
Dk-139
Inhibitor of NF-kappaB-mediated GROalpha expression, suppressing the TNFalpha-induced invasive capability of MDA-MB-231 human breast cancer cells |
1426059-23-5 |
DCC1815 |
Dk-1-49
Novel autophagonizer, inducing autophagic cell death in apoptosis-defective cell line |
853136-76-2 |
DCC1816 |
Dl0410
Novel acetylcholinesterase inhibitor, promoting synaptic function and neuronal survival, ameliorating cognitive deficits in SAMP8 mice via improved mitochondrial dynamics and increased activity of the NMDAR-CREB-BDNF pathway |
|
DCC1817 |
D-lana-14
Novel potent anti-MRSA agent, disrupting biofilms with no resistance development, sensitizing rifampicin and tetracycline against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa |
|
DCC1818 |
Dlc27-14
Specific protein disorder catalyzer of HIV-1 Nef |
1360869-92-6 |
DCC1819 |
Dl-threo-dihydrosphingosine
Competitive inhibitor of both SPHK1 and SPHK2 |
2304-75-8 |
DCC1820 |
D-luciferin Phosphate Sodium Salt
Ultrasensitive bioluminogenic enzyme substrate |
145613-12-3 |
DCC1821 |
D-lys(z)-pro-arg-pna
Chromogenic peptide substrate, being highly sensitive for the measurement of activated Protein C. |
108963-69-5 |
DCC1822 |
Dma-cpptl
Prodrug of CPPTL, inducing apoptosis in a dose-dependent manner via the ROS/JNK pathway in acute myeloid leukemia |
|
DCC1823 |
Dmako-20
Novel multi-target anticancer prodrug activated by the tumor specific CYP1B1 enzyme, potently inhibiting HCT-15, HCT-116 and K562 cells growth, showing moderate anti-proliferative activity towards MDA-MB-231, HepG2, PANC, Bel7402 and MGC803 cancer cells, |
|
DCC1824 |
Dmako-5
Novel antineoplastic agent, exhibiting remarkable anticancer activity as well as excellent cellular selectivity |
|
DCC1825 |
D-mannuronic Acid [6906-37-2]
Novel blocker of the TLR2 and TLR4 downstream signaling pathway, effectively inhibiting mRNA expression of MyD88 and p65, major subunit of nuclear factor-kappaB |
6906-37-2 |
DCC1826 |
Dmb213
Novel non-nucleoside inhibitor of Zika viral RNA-dependent RNA polymerase (RdRp) enzymes |
|
DCC1827 |
Dmcl1-2
Novel potent and selective PROTAC degrader of myeloid cell leukemia 1 (MCL1) |
2351218-88-5 |
DCC1828 |
Dmnpe-caged Luciferin
Novel cell permeable caged Luciferin |
223920-67-0 |
DCC1829 |
Dmocptl
Novel inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells |
|
DCC1830 |
Dmt-dalda
Potent and highly selective µ opioid agonist |
|
DCC1831 |
Dmxb-a
Novel,orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor |
148372-04-7 |
DCC1832 |
Dna Primase Inhibitor-1
Novel DNA primase inhibitor |
874787-49-2 |
DCC1833 |
Dna Primase Inhibitor-13
Novel DNA primase inhibitor |
261363-54-6 |
DCC1834 |
Dnac-1
Novel potentiator of β-lactam activity against Gram positive and Gram negative pathogens |
1006021-30-2 |
DCC1835 |
Dndi-0690
Novel antitubercular and antiparasitic agent, possessing excellent in vitro activity against both L. donovani and Leishmania infantum as well as displaying a better safety profile |
|
DCC1836 |
Do-601
Analeptic agent, stimulating central nervous system; Anti-barbiturate-overdose |
100252-00-4 |
DCC1837 |
Dolastatin 10
Featured
Highly potent cytotoxic microtubule inhibitor |
110417-88-4 |
DCC1838 |
Doot-2d
Selective MAO-B inhibitor |
1522345-35-2 |
DCC1839 |
Dora 42
Dual orexin receptor antagonist (OX1R and OX2R antagonist or DORA) |
1030377-48-0 |
DCC1840 |
Doramectin
Anthelmintic, for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites in cattle |
117704-25-3 |
DCC1841 |
Dothiepin Hydrochloride
Tricyclic antidepressant (TCA), acting as a serotonin–norepinephrine reuptake inhibitor (SNRI) and also having other activities including antihistamine, antiadrenergic, antiserotonergic, anticholinergic, and sodium channel-blocking effects |
25627-36-5 |
DCC1842 |
Dov51892
Agonist of GABAA receptors α15 subunits |
864673-91-6 |
DCC1843 |
Dp-326
Novel antibacterial with activity against the Gram-negative bacteria associated with nosocomial infections |
|
DCC1844 |
Dpa-154
Novel effective and selective inhibitor of E. coli topoisomerase I |
|
DCC1845 |
Dpb163-ae
Novel 2-aminoethyl diphenylborinate (2-APB) analogue, inducing a profound activation of SOCE in DT40 cells, albeit at low concentrations (10 nM), blocking the melatonin-induced [Ca ] cyt increase and SOCE in P. falciparum. |
|
DCC1846 |
Dpbx-l-dopa
Novel boron-containing dopa-derivative, acting as a bladder relaxant through non-catecholamine receptors |
|
DCC1847 |
Dp-c-1
Novel Dual PROTAC for Simultaneous Degradation of EGFR and PARP |
|
DCC1848 |
Dpf-p10
First Potent Small Molecule Ligand for MALAT1 |
|
DCC1849 |
Dpi-287
Novel highly selective agonist for the δ-opioid receptor, producing less convulsions than most drugs from this family and having antidepressant-like effects |
|
DCC1850 |
Dpp7-in-5385
Novel inhibitor of dipeptidyl peptidase 7 (DPP7) |
|
DCC1851 |
Dpp8/9-in-8j
Novel selective DPP8/9 inhibitor, blocking AML progression in vivo |
|
DCC1852 |
Dppe Hydrochloride
Substrate of CYP3A and inhibitor of P-glycoprotein |
92981-78-7 |
DCC1853 |
Dpre1-in-377790
Novel DprE1 inhibitor, killing M. tuberculosis |
634167-64-9 |
DCC1854 |
D-propargylglycine
Click chemistry tool molecule in probing peptidoglycan (PG) |
198774-27-5 |
DCC1855 |
Dp-v-4
Novel Dual PROTAC for Simultaneous Degradation of EGFR and PARP |
|
DCC1856 |
Dri-c23041
Novel inhibitor of the interaction of hACE2 with the spike proteins of SARS-CoV-2 as well as SARS-CoV |
|
DCC1857 |
Dri-c91005
Novel inhibitor of the interaction of hACE2 with the spike proteins of SARS-CoV-2 as well as SARS-CoV |
|
DCC1858 |
Dropropizine
Oral non-opioid anti-tussive agent for treatment of cough |
17692-31-8 |
DCC1859 |
Drostanolone Propionate
Inhibitor of the growth of estrogen receptor-presenting breast cancers |
521-12-0 |
DCC1860 |
Ds08210767
Novel potent PTHR1 antagonist |
2376334-75-5 |
DCC1861 |
Ds19161384
Novel selective PPARγ modulator, resulting in robust plasma glucose reductions with excellent DMPK profiles |
|
DCC1862 |
Ds28120313
Novel potent orally active hepcidin production inhibitor |
2146177-09-3 |
DCC1863 |
Ds37571084
Novel and orally bioavailable PTHR1 antagonist |
|
DCC1864 |
Ds-3801b Hydrochloride
Novel non-macrolide GPR38 agonist |
1369414-03-8 |
DCC1865 |
Ds42450411
Novel potent orally active hepcidin production inhibitor |
|
DCC1866 |
Ds79932728
Novel Potent, Orally Available G9a/GLP Inhibitor for Treating β-Thalassemia and Sickle Cell Disease |
|
DCC1867 |
Dsba Inhibitor F1
Pathogen motility inhibitor of EcDsbA |
859833-20-8 |
DCC1868 |
Dshs00884
Non-toxic human papillomavirus E6 inhibitor |
675104-49-1 |
DCC1869 |
Dsm-338
Novel Plasmodium falciparum Dihydroorotate Dehydrogenase (PfDHODH) Inhibitor (Pfalcip cells: 0.0018 μM) |
|
DCC1870 |
Dsm502
Featured
Novel potent inhibitor of dihydroorotate dehydrogenase (DHODH) |
2426616-55-7 |
DCC1871 |
Dsm705
Novel potent Dihydroorotate Dehydrogenase (DHODH) inhibitor |
2653225-38-6 |
DCC1872 |
Dsr-98776
Novel selective mGlu5 receptor negative allosteric modulator (NAM) with potent antidepressant and antimanic activity |
|
DCC1873 |
Ds-sg-44
Agonist of S1P receptors |
|
DCC1874 |
Dt-061
Novel potent and orally active activator of PP2A |
1809427-19-7 |
DCC1875 |
Dt2216nc
Negative control for DT2216 |
|
DCC1876 |
Dtagv-1
Potent and selective degrader of mutant FKBP12F36V fusion proteins |
|
DCC1877 |
Du-34569 Maleate
Antiviral agent against influenza A, parainfluenza Sendai, coxsackie A21, and rhinovirus |
34522-38-8 |
DCC1878 |
Duocarmycin A
Irreversible DNA minor groove binding alkylating agent, disrupting the nucleic acid architecture and leading to tumor cell death |
118292-34-5 |
DCC1879 |
Dutomycin
Anthracycline antibiotic from Streptomyces |
146663-67-4 |
DCC1880 |
Dv-7028
Selective 5-HT2A receptor antagonist |
133364-63-3 |
DCC1881 |
Dv-7028 Hydrochloride
Potent and selective 5-HT 2A receptor antagonist |
133364-62-2 |
DCC1882 |
Dw10075
Novel potent and highly selective inhibitor of VEGFR, exhibiting antitumor activities both in vitro and in vivo. |
1804982-31-7 |
DCC1883 |
Dw-1350
Novel and potent leukotriene B(4) receptor antagonist |
491577-61-8 |
DCC1884 |
Dwn-723-23
Novel Hsp70 agonist, showing no cellular toxicity and induced cellular stress response pathways |
|
DCC1885 |
Dx2-hsp70 Inhibitor-1
Novel allosteric inhibitor of the tumor-promoting interaction between the oncogenic factor AIMP2-DX2 and HSP70 |
125105-17-1 |
DCC1886 |
Dx-52-1
Antitumor antibiotic |
96251-59-1 |
DCC1887 |
Dy3002
Novel Selective and Potent EGFR Inhibitor, Overcoming T790M-Mediated Resistance in Non-Small Cell Lung Cancer |
2020015-37-4 |
DCC1888 |
Dy428174
Novel potent Inhibitor of PI3Kalpha |
1202041-71-1 |
DCC1889 |
E09241
Novel OPG/RANKL upregulator, increasing OPG expression without affecting RANKL expression, promoting osteoblast differentiation while inhibiting osteoclast differentiation, regulating OPG expression through canonical Wnt/β-catenin signaling |
1043110-13-9 |
DCC1890 |
e2012-bpyne
γ-Secretase modulator (GSM) photoaffinity probe, revealing distinct allosteric binding sites on presenilin |
1430800-80-8 |
DCC1891 |
E235-1756
Potent Activator of P53-Independent Cellular Senescence |
891894-69-2 |
DCC1892 |
E3-ligase Degrader 10
Novel XIAP BIR2 domain-binding degrader of E3 ubiquitin ligases |
|
DCC1893 |
E-5842 Citrate
Sigma1 receptor ligand and potential atypical antipsychotic |
220120-14-9 |
DCC1894 |
Ea-b3a
Novel degrader of GST-α and GST-α-EGFP fusion proteins as well as endogenous GST-π in cells and lysates |
|
DCC1895 |
Ebi-13a
Highly potent and selective activator of isozymes CA-VA and CA-VII |
147596-31-4 |
DCC1896 |
Ebmi-13b
Highly potent and selective activator of isozymes CA-VA and CA-VII |
21202-53-9 |
DCC1897 |
Ebopiprant
Novel Oral and Selective Prostaglandin F 2α (PGF 2α ) Receptor Antagonist |
2005486-31-5 |
DCC1898 |
Ebov-in-c31
Novel PP1-targeting Ebola Virus (EBOV) inhibitor with improved pharmacological properties |
752216-12-9 |
DCC1899 |
Ebselen Oxide
Novel dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9, inhibiting Pseudomonas aeruginosa alginate synthesis |
104473-83-8 |
DCC1900 |
Ebv Activator C60
Novel EBV activator, well-performing EBV lytic cycle inducer |
1031658-01-1 |
DCC1901 |
Ecdsbb-in-12
Novel potent specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme |
112749-52-7 |
DCC1902 |
Ecdsbb-in-9
Novel specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria |
41933-33-9 |
DCC1903 |
Echinoside A
Novel marine-derived anticancer saponin, targeting topoisomerase2alpha by unique interference with its DNA binding and catalytic cycle |
75410-53-6 |
DCC1904 |
Ecraprost
Lipo-pro-prostaglandin E1, preventing hearing disturbance and equilibrium dysfunction due to inner ear microcirculatory disorders |
136892-64-3 |
DCC1905 |
Edoxaban Isomer
An impurity of Edoxaban, a novel inhibitor of factor Xa |
1255529-24-8 |
DCC1906 |
Eef2k-in-21i
Novel eEF2K inhibitor, inducing significant apoptosis through classical apoptotic pathways |
|
DCC1907 |
Efatutazone
Potent agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity |
223132-37-4 |
DCC1908 |
Efonidipine
Calcium channel blocker, blocking both T-type and L-type calcium channels |
111011-63-3 |
DCC1909 |
Efrapeptin F
Natural alpha-aminobutyric acid-rich secondary metabolite of fungi, strongly inhibiting the BBMV V-ATPase, acting as a mitochondrial complex V inhibitor, showing antitumor activity in vivo |
131353-66-7 |
DCC1910 |
Efrotomycin
Antibiotic, inhibiting bacterial protein synthesis |
56592-32-6 |
DCC1911 |
Egfr T790m Inhibitor 6a
Novel third-generation EGFR tyrosine kinase inhibitor, targeting EGFR T790M mutation in advanced non-small cell lung cancer |
|
DCC1912 |
Egfr-in-451
Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis |
220576-72-7 |
DCC1913 |
Egfr-in-542
Novel EGFR inhibitor, significantly reducing myocardial inflammation, fibrosis, apoptosis, and dysfunction, showing promises to the treatment on obesity-induced cardiac complications |
1639040-81-5 |
DCC1914 |
Egfr-in-557
Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis |
1639040-91-7 |
DCC1915 |
Egis-11150
Potent inhibitor of adrenergic alpha1, alpha2c, 5-HT2a, 5HT7 receptors; Relatively selective blocker of adrenergic alpha2c over adrenergic alpha2a receptors. |
494861-87-9 |
DCC1916 |
Egis-8332
Selective, non-competitive AMPA receptor antagonist, improving motor co-ordination |
220725-87-1 |
DCC1917 |
Egonol
Antibacterial agent |
530-22-3 |
DCC1918 |
Eh-201
Arginase Inhibitor, activating EPO-mediated mitochondrial function and haemoglobin expression, stimulating melanogenesis by MAP kinase activation and tyrosinase upregulation |
55327-45-2 |
DCC1919 |
Ehi1471
Potent and bio-stable inhibitor of the chicken sEH (chxEH) |
|
DCC1920 |
Ehi2119
Potent and bio-stable inhibitor of the chicken sEH (chxEH) |
|
DCC1921 |
Ehi2225
Potent and bio-stable inhibitor of the chicken sEH (chxEH) |
|
DCC1922 |
Eht5372
Novel Mirk kinase inhibitor, inhibiting DYRK1A-induced Tau phosphorylation at multiple AD-relevant sites, blocking the in vivo growth of pancreatic cancer cells |
1425945-60-3 |
DCC1923 |
Eidd-1619
Novel water-soluble analog of progesterone |
1659302-92-7 |
DCC1924 |
Eidd-1723
Novel water-soluble analog of progesterone, reducing cerebral edema and lesion size and improving functional recovery, decreasing glial fibrillary acidic protein expression immunoreactivity |
1659302-89-2 |
DCC1925 |
Eif4a Inhibitor 28
Novel RNA-competitive, ATP-uncompetitive eIF4A Inhibitor, decreasing BJAB Burkitt lymphoma cell viability, engaging a novel pocket in the RNA groove of eIF4A and inhibiting unwinding activity by interfering with proper RNA binding and suppressing ATP hydr |
|
DCC1926 |
Ejmch-6
Novel anti-bacterial agent, targeting the MmpL3 transporter in Mycobacterium abscessus |
|
DCC1927 |
Ejr-866-75
Novel Cell-active Inhibitor of the Undrugged Oncogenic PTP4A3 Phosphatase |
|
DCC1928 |
Ejr-866-81
Novel Cell-active Inhibitor of the Undrugged Oncogenic PTP4A3 Phosphatase |
|
DCC1929 |
El-0052
Novel etomidate analogue, enhancing GABA A receptors currents with a concentration for 50% of maximal effect (EC 50 ) of 0.98 {plus minus} 0.02 μM, which was about three times more potent than etomidate (3.07 {plus minus} 1.67 μM), retaining the favorable |
|
DCC1930 |
El-228
Novel inhibitor of Aurora B kinase |
|
DCC1931 |
Ela23-32
Novel ligand of the apelin receptor (APJ), possessing high affinity for APJ (Ki 4.6 nM) and producing cardiorenal effects in vivo similar to those of ELA |
|
DCC1932 |
elaidyl-sulfamide
Oleoylethanolamide-modelled PPAR |
945009-57-4 |
DCC1933 |
Elnd006
Novel γ-secretase inhibitor |
959997-22-9 |
DCC1934 |
Elovl1 Inhibitor 22
Novel highly potent, selective, and CNS-penetrant inhibitor of elongation of very long chain fatty acid 1 (ELOVL1) enzyme |
|
DCC1935 |
Elx-02
Eukaryotic Ribosomal Selective Glycoside (ERSG), inducing read-through of premature stop codons (PSCs) and resulting in translation of full-length protein |
1375073-95-2 |
DCC1936 |
Em20-25
Novel BCL-2 inhibitor, neutralizing the antiapoptotic activity of overexpressed BCL-2 toward staurosporine and sensitizing BCL-2-expressing cells from leukemic patients to the killing effects of staurosporine, chlorambucil, and fludarabine |
141266-44-6 |
DCC1937 |
em-800
High affinity ligand for estrogen receptor- |
182167-03-9 |
DCC1938 |
Emac4001
Novel potent antitumor agent, inducing apoptosis in a panel of tumor cell lines |
|
DCC1939 |
Emd-1204831
Novel potent and highly selective c-Met inhibitor |
1362819-72-4 |
DCC1940 |
Emd57439
PDE 3 inhibitor |
148714-88-9 |
DCC1941 |
Emd-66684
Non-peptide angiotensin II receptor antagonist |
187683-79-0 |
DCC1942 |
Emdb-1
Novel peptide endomorphin (EM) degradation blocker |
|
DCC1943 |
Emdb-2
Novel peptide endomorphin (EM) degradation blocker |
|
DCC1944 |
Emdb-3
Novel peptide endomorphin (EM) degradation blocker |
|
DCC1945 |
Emicerfont
Novel corticotropin-release factor 1 antagonist |
786701-13-1 |
DCC1946 |
Emitefur
5-FU derivative, with various anticancer agents against human cancer xenografts |
110690-43-2 |
DCC1947 |
Eml108
Novel PRMT inhibitor, preventing arginine methylation of cellular proteins, being essentially inactive against the lysine methyltransferase SET7/9 |
|
DCC1948 |
Eml981
Novel Potent and Selective Inhibitor of Protein Arginine Methyltransferase 4 (PRMT4) |
|
DCC1949 |
Emoxypine Succinate
Antioxidant, inhibiting free radical oxidation of biomembrane lipids, modulating the activity of membrane-bound enzymes and the receptor complexes of the brain membranes |
127464-43-1 |
DCC1950 |
En3356
Novel non-steroidal CYP17 inhibitor. reducing androgen synthesis for treatment of castration-resistant prostate cancer |
1429329-63-4 |
DCC1951 |
Ena739155
Novel butyrylcholinesterase inhibitor against Alzheimer's disease |
|
DCC1952 |
Encenicline
Novel Potentiator of α7 Receptor Signaling |
550999-75-2 |
DCC1953 |
Endo-3-aminotropane Dihydrochloride
Useful pharmceutical building block |
5424-16-8 |
DCC1954 |
Endochin
Antimalarial |
354155-51-4 |
DCC1955 |
Endosidin1
Natural vesicle trafficking inhibitor |
57672-91-0 |
DCC1956 |
Endosidin3
Specific inhibitor of trafficking pathways, disrupting recycling at the PM via interference with ROP6/RIC1 signalling |
|
DCC1957 |
Endosidin4
Novel inhibitor of eukaryotic ARF-GEFs (ADP-ribosylation factor guanine nucleotide exchange factors) |
|
DCC1959 |
Endosidin7
Specific inhibitor for plant callose deposition during cytokinesis without affectting endomembrane trafficking during interphase or cytoskeletal organization |
329072-88-0 |
DCC1960 |
Endosidin8.0
Novel modulator of the PIN1 accumulation, selectively modifying PIN1 basal plasma membrane targeting in Arabidopsis with minimal effects on apical plasma membrane proteins |
444286-45-7 |
DCC1961 |
Endosidin8.1
Novel modulator of the PIN1 accumulation, selectively modifying PIN1 basal plasma membrane targeting in Arabidopsis with minimal effects on apical plasma membrane proteins |
|
DCC1962 |
Eniporide Hydrochloride
Sodium/hydrogen exchange inhibitor |
211813-86-4 |
DCC1963 |
Enl-in-7
Novel potent inhibitor of eleven-nineteen leukemia (ENL) protein, selectively targeting the ENL YEATS domain |
|
DCC1964 |
Enmd-2076 Tartrate
Novel oral inhibitor of angiogenic and proliferation kinases, having activity in recurrent, platinum resistant ovarian cancer |
1291074-87-7 |
DCC1965 |
Enpp1 Inhibitor 43
Novel potent inhibitor of ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1 or NPP1), showing good in vitro potency, stability in SGF/SIF/PBS, selectivity, ADME properties and pharmacokinetic profile and finally potent anti-tumor response in viv |
|
DCC1966 |
Enprostil
PGE2 analog, inhibiting gastric acid secretion |
73121-56-9 |
DCC1967 |
Ent Naxagolide Hydrochloride
Dopamine D2-receptor agonist for the treatment of extrapyramidal disorders, also being an antiparkinson agent |
100935-99-7 |
DCC1968 |
Entasobulin
Featured
Entasobulin is a β-tubulin polymerization inhibitor with potential anticancer activity. |
501921-61-5 |
DCC1969 |
Entpd5-in-1a
Novel inhibitor of Ectonucleoside Triphosphate Diphosphohydrolase 5 (ENTPD5) |
|
DCC1970 |
Entpd5-in-2f
Novel inhibitor of Ectonucleoside Triphosphate Diphosphohydrolase 5 (ENTPD5) |
|
DCC1971 |
Ent-verticilide
Unnatural verticilide enantiomer, inhibiting type 2 ryanodine receptor-mediated calcium leak and being antiarrhythmic. |
|
DCC1972 |
Ep-7041
Novel, potent, and selective Factor XIa inhibitor |
1803271-50-2 |
DCC1973 |
Epc-k1
Vitamin E derivative, suppressing inflammation during hepatic ischemia-reperfusion injury and exerting hepatoprotective effects |
127061-56-7 |
DCC1974 |
Epetraborole R-mandelate
Novel potent and selective leucyl-tRNA synthetase inhibitor |
1234563-15-5 |
DCC1975 |
Epha2-agonist-27
Novel agonist of EphA2 receptor tyrosine kinase |
|
DCC1976 |
Ephb1-in-10
Potent and selective covalent inhibitor of receptor tyrosine kinase EphB1 |
|
DCC1977 |
Ephb3-in-10
Novel clickable potent and specific inhibitor of EphB3 |
|
DCC1978 |
Ephb3-in-9
The first potent and specific inhibitor of a single Eph isoform EphB3 |
|
DCC1979 |
Epi-0023
Novel selrctive SETD8 inhibitor without inhibiting G9a, SETD7, RmtA, and PRMT1 |
3963-80-2 |
DCC1980 |
Epibestatin Hydrochloride
Novel stabilizer of 14-3-3 PPIs, Diastereoepimer of aminopeptidase inhibitor bestatin |
100992-60-7 |
DCC1981 |
Epinastine Hydrobromide
Second-generation antihistamine and mast cell stabilizer, being highly selective for the H1 receptor |
127786-29-2 |
DCC1982 |
Epi-nocardicin G
The precursor of the nocardicins |
|
DCC1983 |
Eprazinone
Mucolytic and bronchospasm relieving agent |
10402-90-1 |
DCC1984 |
Eps-in-1
Novel inhibitor of extracellular polymeric substances (EPS) |
|
DCC1985 |
Eptapirone Fumarate
Potent, selective, high efficacy 5-HT1A receptor agonist |
179756-85-5 |
DCC1986 |
Epz005687n
Inactive isomer of EPZ005687 and can be used as the negative control for EPZ005687 |
|
DCC1987 |
Epz028862
Novel selective SMYD3 inhibitor |
|
DCC1988 |
Epz032597
Novel selective SMYD2 inhibitor |
|
DCC1989 |
Epz033294
Novel SMYD2 inhibitor |
|
DCC1990 |
Er Degrader 40
Novel Oral Selective Estrogen Receptor Degrader with Highly Improved Antitumor Effect and Favorable Druggability |
|
DCC1991 |
Er-119884
Selective squalene synthase (SQS) inhibitor |
|
DCC1992 |
Er-38925
Retinoic acid receptor (RAR) subtype α-selective agonist |
196517-43-8 |